Background Anthracyclines are important chemotherapeutic agents, but their use is limited by cardiotoxicity. Candidate gene and genome-wide studies have identified putative risk loci for overt cardiotoxicity and heart failure, but there has been no comprehensive assessment of genomic variation influencing the intermediate phenotype of anthracycline-related changes in left ventricular (LV) function. The purpose of this study was to identify genetic factors influencing changes in LV function after anthracycline chemotherapy.
Methods We conducted a genome-wide association study (GWAS) of change in LV function after anthracycline exposure in 385 patients identified from BioVU, a resource linking DNA samples to de-identified electronic medical record data. Variants with P values less than 1 × 10 − 5 were independently tested for replication in a cohort of 181 anthracycline-exposed patients from a prospective clinical trial. Pathway analysis was performed to assess combined effects of multiple genetic variants.
Results Both cohorts were middle-aged adults of predominantly European descent. Among 11 candidate loci identified in discovery GWAS, one single nucleotide polymorphism near PR domain containing 2, with ZNF domain (PRDM2), rs7542939, had a combined P value of 6.5 × 10 − 7 in meta-analysis. Eighteen Kyoto Encyclopedia of Gene and Genomes pathways showed strong enrichment for variants associated with the primary outcome. Identified pathways related to DNA repair, cellular metabolism, and cardiac remodeling.
Conclusion Using genome-wide association we identified a novel candidate susceptibility locus near PRDM2.
Variation in genes belonging to pathways related to DNA repair, metabolism, and cardiac remodeling may influence changes in LV function after anthracycline exposure. Pharmacogenetics and Genomics 27:247-254 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Anthracyclines are important chemotherapeutic agents, but their use is limited by cardiotoxicity that characteristically manifests as progressive systolic dysfunction [1] . Many mechanisms for cardiotoxicity have been proposed, including production of reactive oxygen species [2] and alterations in anthracycline metabolism and transport [3, 4] . More recent data suggest anthracycline-mediated inhibition of topoisomerases, in particular, topoisomerase IIβ and mitochondrial topoisomerase I, is central to cardiotoxicity, producing double strand DNA breaks, activation of apoptotic pathways, and ultimately impaired mitochondrial function and decreased mitochondrial biogenesis [5, 6] . Anthracyclines also impair sarcomere maintenance, disrupt cell survival signaling, and impair cellular fatty acid metabolism [2, 7] .
Anthracycline cardiotoxicity is dose-dependent at a population level, but substantial interindividual variability makes it difficult to predict which patients will be Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pharmacogeneticsandgenomics.com).
affected even when cumulative exposure and clinical parameters are known, indicating influences beyond dose and known risk factors play a substantial role in susceptibility. Several genetic variants influencing development of overt cardiotoxicity and heart failure have been implicated by candidate gene analyses and genome wide association studies (GWAS), primarily in childhood cancers [8] [9] [10] [11] [12] [13] . Nevertheless, known genetic factors do not explain all the observed variability in susceptibility.
Common definitions of anthracycline-induced cardiotoxicity require a significant decrease in cardiac function or clinical evidence of cardiac insufficiency [11, 13] . However, dichotomous classifications have limitations, as more subtle effects may be meaningful, and even severe cardiac dysfunction can be asymptomatic. Indeed, continuous measures of left ventricular (LV) structure and function in the general population are both heritable and associated with important cardiovascular outcomes [14] . The quantitative change in LV function is an intermediate phenotype of anthracycline-induced cardiotoxicity, and, importantly, early reductions in this metric are associated with later development of overt cardiotoxicity [15] . However, the genomic influences on anthracyclineinduced alterations in cardiac function, particularly in adults, have not been studied in a genome-wide, unbiased fashion. Understanding the genomics of this intermediate phenotype may help characterize quantitative, mechanistic aspects of cardiotoxicity and form the basis for identification of at-risk individuals and implementation of measures to minimize or prevent toxicity.
Methods

Study populations
Discovery genome-wide association study
The discovery dataset was generated from BioVU (Nashville, Tennessee, USA), a Vanderbilt resource linking DNA samples to de-identified electronic medical records (EMR). The development, implementation, and use of BioVU as a platform for discovery has been previously described [16, 17] . In a minority of cases, baseline LVEF and cumulative anthracycline dose were not documented in patients with otherwise complete information. These data were imputed using multiple imputation implemented in SPSS statistical software, version 20 (IBM Corp., Armonk, New York, USA).
Replication
The replication dataset was drawn from patients enrolled in the 'Patients undergoing anthracycline-based chemotherapy to assess the effectiveness of using biomarkers to detect and identify cardiotoxicity and describe treatment' (PREDICT) study (ClinicalTrials.gov number: NCT01311843). PREDICT is a multicenter study with coordinating sites at MD Anderson Cancer Center (Houston, Texas, USA) and Vanderbilt University Medical Center (Nashville, Tennessee, USA). The study protocol was approved by the Institutional Review Boards of both institutions. At enrollment, patients were at least 18 years of age, had an LVEF of 50% or more, and were starting a new course of chemotherapy that included an anthracycline. Previous chemotherapy exposure, including anthracyclines, was not an exclusion criteria. Patients underwent serial assessment of cardiac function with transthoracic echocardiography at baseline, 6 and 12 months after initiation of chemotherapy, or if indicated clinically. To ensure no Patients were included in both discovery and replication populations, only patients from outside Vanderbilt were considered for inclusion.
Genotyping and imputation
BioVU patients were genotyped in the Vanderbilt Technologies for Advanced Genomics Core using the Illumina Omni 1-Quad platform (Illumina Inc., San Diego, California, USA). Preimputation quality control filters were applied at the sample level (exclusion criteria: call rate < 98%, sex discrepancy, relatedness, duplicate discordance, and HapMap discordance) and single nucleotide polymorphism (SNP) level (exclusion criteria: call rate < 98%, replicate discordance, and Mendelian errors). Genotypes were imputed to 1000 Genomes Phase 1, version 3 (19 April 2012) using IMPUTE2 software (Department of Statistics, University of Oxford, Oxford, UK) [19] and reference panels from all 1000 Genomes populations, and alleles with confidence of greater than 0.9 were retained (Supplementary Methods, Supplemental digital content 1, http://links.lww.com/FPC/B211). Candidate SNPs with P values less than 1 × 10 − 5 in discovery were genotyped in the replication cohort using the Sequenom MassArray genotyping system (Agena Bioscience Inc., San Diego, California, USA). Quality control parameters included sample genotyping efficiency of more than 90% and SNP genotyping efficiency of more than 95%.
Statistical analysis
The primary outcome was the maximal change in LVEF from prechemotherapy measurement. This intermediate phenotype was chosen because changes in this parameter are used in clinical practice to define and detect anthracycline cardiotoxicity. If LVEF increased from baseline, the maximum positive change and cumulative chemotherapy dose up to that timepoint was recorded. When LVEF decreased from the baseline, the maximum negative change and cumulative chemotherapy to that timepoint were recorded. When both positive and negative changes from the baseline LVEF were present, the maximum negative change and cumulative chemotherapy to that timepoint were recorded.
In discovery GWAS, multiple linear regression, implemented in PLINK, was used to test for the association between SNPs and change in LVEF adjusting for age, sex, baseline LVEF, cumulative anthracycline dose at the time of outcome LVEF, follow-up time from start of anthracycline, number of cardiac risk factors (hypertension, diabetes, coronary artery disease, dyslipidemia, smoking), and concomitant trastuzumab. All patients were included regardless of ancestry, and principal components one and two (which explained 28% of the variance in the genetic data) were included to adjust for possible population stratification ( Supplementary Fig. 1 , Supplemental digital content 2, http://links.lww.com/FPC/B212 and Supplementary Fig. 2 , Supplemental digital content 3, http://links.lww.com/FPC/ B213). Only SNPs with minor allele frequency of at least 0.05 were included in analyses. A priori genome-wide significance was defined as 5 × 10
. Lead SNPs from loci with P values less than 1 × 10 − 5 in the discovery GWAS were tested for association in the replication cohort. Analysis again utilized multiple linear regression with clinical covariates as in discovery, with the exception of the substitution of selfreported ancestry for principal components. Analysis was conducted using the R statistical package (The R Foundation for Statistical Computing, Vienna, Austria). The combined P value from the discovery GWAS and replication for each SNP were determined using inverse variance based meta-analysis (Supplementary Methods, Supplemental digital content 1, http://links.lww.com/FPC/B211).
Pathway-based genome-wide association study
Pathway analysis was performed with the Pathway Analysis by Randomization Incorporating Structure software package (Biomedical and Translational Informatics Laboratory, Pennsylvania State University, State College, Pennsylvania, USA) [20] . SNPs were first assigned to gene boundaries on the basis of genomic location. Genes, in turn, were assigned to functional networks, which were tested for over-representation of SNPs that were observed to be nominally associated with change in LVEF in the single-SNP GWAS. As the aim of pathwaybased analysis was to extend on the single-SNP GWAS and identify cumulative effects on change in LVEF that related to multiple SNPs, with individually smaller effects, we set a less stringent threshold and significant SNPs were defined as those with P values of 0.05 or less from the discovery GWAS. Biological pathways were defined on the basis of the KEGG pathway database [21] . A total of 290 KEGG pathways were evaluated for overrepresentation of SNPs significantly associated with change in LVEF. To determine P values for overall association of pathways, permutation tests were conducted comparing pathways defined in the KEGG database to random pathways generated from regions across the genome having similar linkage disequilibrium structure (as predicted on the basis of control individuals of European ancestry available in the HapMap population). We chose to generate random pathways for permutation tests using the linkage disequilibrium structure predicted for individuals of European ancestry as the majority of the analysis dataset (∼84%) that was evaluated in the single-SNP GWAS, from which the P values for SNPs were derived, represented this ancestral group. The number of SNPs significantly associated with change in LVEF assigned to each evaluated KEGG pathway were compared with the number of significantly associated SNPs in 3500 randomly generated pathways. On the basis of this number of permutation tests, we chose a stringent significance threshold of P value of 2.86 × 10 − 4 for pathway-based results, which corresponded to a false discovery rate-corrected P value of 0.05 or less.
To better understand the relationship of associated pathways to risk for change in LVEF, pathways that were significantly associated were further subjected to permutation-based investigations to identify 'core' genes driving overall pathway associations. 'Core' genes were defined as genes whose P value in the context of the biological pathway was less than 0.001.
Results
Discovery and replication cohort identification
Search of BioVU identified 385 patients with anthracycline exposure, measures of LVEF, and available DNA samples ( Supplementary Fig. 3 , Supplemental digital content 4, http://links.lww.com/FPC/B214). Patients had a median age of 52 years [interquartile range (IQR): 40-61 years], 58% were female, and 88% were White. Non-Hodgkin's lymphoma and breast cancer were the most common malignancies. Median baseline LVEF was 64% (IQR: 60-68%) and the median change in LVEF from baseline was − 6% (IQR: 0 to − 12%) with a range of GWAS of LV function after anthracycline Wells et al. 249 22 to − 47% (Fig. 1a) . The median anthracycline exposure (doxorubicin equivalents) was 240 mg/m 2 (IQR: 180-300 mg/m 2 ). The median time from baseline LVEF to anthracycline exposure was 6 days (IQR 2-13 days), and median follow-up between chemotherapy initiation and outcome LVEF was 348 days (IQR: 122-755 days) ( Table 1) . Radionuclide ventriculography and transthoracic echocardiography accounted for over 95% of both prechemotherapy (74% radionuclide ventriculography; 24% transthoracic echocardiography) and outcome (50% radionuclide ventriculography; 46% transthoracic echocardiography) LVEF observations. Baseline LVEF and cumulative anthracycline dose were imputed for 74 (19%) and two (0.5%) patients, respectively.
The replication cohort included 181 PREDICT patients with adequate DNA samples and complete phenotype data ( Supplementary Fig. 4 , Supplemental digital content 5, http://links.lww.com/FPC/B215). Patients had a median age of 53 years (IQR: 45-61 years), 87% were female, and 84% were White. Breast cancer was the most common malignancy. The median baseline LVEF was 64% (IQR: 60-68%), and the median change in LVEF was − 4% (IQR: 3 to − 9%) with a range of 16 to − 28% (Fig. 1b) . The median anthracycline dose was 224 mg/m 2 (IQR: 60-241 mg/m 2 ), with a median follow-up from start of chemotherapy of 217 days (IQR: 180-364 days) ( Table 2) , and a minority of patients (< 5%) had previous exposure to chemotherapy.
Discovery genome-wide association study and replication
After imputation and quality control, 4 429 986 markers were included in the discovery GWAS. A single locus on chromosome 1 (1p32.1) reached genome-wide significance with a P value of 2.7 × 10 − 8 for the lead SNP rs10443221, which conferred protection (β = 4.11; SE: 0.74) from cardiotoxicity (i.e. change in LVEF was 4.11 points higher for each alternate allele). The nearest characterized gene is CYP2J2. Ten other loci had P values less than 1.0 × 10 − 5 , including rs7542939 at 1p36.21 ( Fig. 2; Supplementary Fig. 5 , Supplemental digital content 6, http://links.lww.com/FPC/B216 and Supplementary Fig. 6 , Supplemental digital content 7, http://links.lww.com/FPC/B217). Lead SNPs from all 11 loci were carried forward for testing in the replication cohort. Results of association testing for discovery and replication are summarized in Table 3 . One locus, 1p36.21, successfully replicated with the lead SNP rs7542939 having a P value of 0.01. This SNP had an overall minor allele frequency of 0.15 and conferred increased risk (overall β = − 3.82; SE: 0.77) for a decrease in LVEF. The combined P value from meta-analysis for this SNP was 6.5 × 10 − 7 . The nearest annotated gene, PRDM2, is~40 kb upstream and encodes an H3K9 methyltransferase that regulates gene expression through modification of chromatin at target genes promoters [22] . No association between SNP rs10443221 and change in LVEF was observed in the replication cohort (β = − 1.2; SE: 0.80; P = 0.14).
Pathway-based genome-wide association study There were 18 KEGG pathways with strong evidence (P < 2.86 × 10 − 4 ) of enrichment for SNPs associated with changes in LVEF (Supplementary Table 1 , Supplemental digital content 8, http://links.lww.com/FPC/ B218). Five pathways were directly related to cellular metabolism and mitochondrial function, including: synthesis and degradation of ketone bodies, ubiquinone and other terpenoid-quinone biosynthesis, D-glutamine and D-glutamate metabolism, PPAR signaling pathway, and aminoacyl-tRNA biosynthesis (whose association was driven by genes coding for mitochondrial aminoacyltRNA synthetases). Associations of five additional pathways, N-glycan biosynthesis, glycosaminoglycan degradation, Wnt signaling, notch signaling, and axon guidance were driven by genes previously implicated in cardiac remodeling. Also enriched was the DNA repair pathway base excision and repair.
Discussion
We conducted a GWAS and pathway analysis of change in LVEF after exposure to anthracycline chemotherapy. Our GWAS results suggest a novel candidate susceptibility locus at chromosome 1p36.21 near PRDM2, and pathway analysis highlights the multifactorial nature of anthracycline cardiotoxicity and points toward processes involved in cellular metabolism/energetics, myocardial remodeling, and genome repair as central contributors to susceptibility.
Although we cannot say with certainty that the observed association at 1p36.21 is functionally related to PRDM2, there are several features that make it a biologically plausible candidate gene. PRDM2 is critical for BRCA1-dependent repair of DNA double-strand breaks [23] , and impairment of this mechanism exacerbates doxorubicin cardiotoxicity in mice [24] . In addition, PRDM2 is a transcriptional regulator of heme-oxygenase-1 [25] , which, in addition to its role in protection from oxidative stress [26, 27] , has been shown to facilitate the repair of doxorubicin-induced DNA double-strand breaks in vitro [28] and reduce cardiomyocyte apoptosis in doxorubicin-exposed mice [29] .
Although the association between rs10443221 and change in LVEF observed in the discovery GWAS was not replicated, CYP2J2 also has biologic plausibility as a candidate gene. CYP2J2 converts arachidonic acid to epoxyeicosatrienoic acids (EETs), whose cardiovascular effects include systemic and coronary vasodilation [30] , anti-inflammatory actions [31] , and promotion of angiogenesis [32] . Exogenous EETs attenuate doxorubicininduced mitochondrial damage in vitro, and mice with cardiac specific overexpression of human CYP2J2 show reduced cardiomyocyte apoptosis, lower levels of biomarkers of myocardial injury and oxidative stress, and improved cardiac function after exposure to anthracyclines [33] . These functional data may support the measurement of EET's and CYP2J2 function in future studies of anthracycline cardiotoxicity. It was expected that common variants may have cumulative effects on LV function, and that genetic factors contributing smaller effects (odds ratio ≤1.5) would be overlooked in the typical single-SNP approach to analysis of GWAS data. Pathway-based analysis identified 18 KEGG pathways associated with the change in LV function. DNA injury is an important proximal effect of anthracyclines, and associations with pathways involved in DNA repair are not surprising. Similarly, the heart has very high energy requirements, and heart failure from any cause, particularly when advanced, is associated with myocardial energy depletion, derangement of mitochondrial function and biogenesis, and a general shift in substrate preference from fatty acids to glucose [34, 35] . The observed associations in energetic pathways may suggest that susceptible individuals have less 'metabolic reserve' in the face of myocardial injury. Pathway analysis also identified several cellular components and processes previously implicated in myocardial remodeling and response to injury, including glycosylation [36, 37] , constituents of the extracellular matrix [38] , and proteins involved in extracellular matrix-receptor interaction [39] [40] [41] . In addition, two important signaling pathways, wnt and notch, also showed evidence for enrichment. The role of both pathways in cancer and metastasis is well established [42, 43] ; they are also important for induction of pathologic hypertrophy, cardiac remodeling, and response to various forms of myocardial injury including infarction and pressure overload [44] [45] [46] [47] [48] . The diversity of pathways implicated reinforce the complexity of anthracycline cardiotoxicity and may point toward therapeutic targets.
It is interesting that we did not detect associations with many previously implicated susceptibility factors for anthracycline related cardiotoxicity [11, 13, 49] . Difficulty replicating associations between candidate variants and important human phenotypes has been described [50] . It may be that we were underpowered to detect small effect Manhattan plot of discovery genome-wide association study of change in left ventricular ejection fraction (LVEF). Results for each variant are organized according to chromosomal position on the X-axis, with − log 10 (P values) for association of genotype to change LVEF from the discovery cohort on the Y-axis. The horizontal line indicates the a priori threshold for statistical significance. sizes. It is also possible that some published associations are false positives. However, this observation may be related to important differences among studies including population demographics, treatment, comorbidities, follow-up duration, and definition of toxicity.
Results of our study should be interpreted within its limitations. The cohorts used are relatively small, and we were likely underpowered to detect effects of the modest size. In addition, variability in LVEF measurements due to inherent limitations of cardiac imaging and lack of standardized protocols in the discovery cohort (e.g. assessments were clinically indicated and not at prespecified intervals, contrast was not universally used, LVEF measurements were made using both quantitative and visual estimation methods, and use of different modalities for pretherapy and post-therapy LVEF determination) could have introduced bias. Finally, we did not perform functional studies to further establish a mechanistic link between the locus tagged by SNP rs7542939 and cardiotoxicity. However, previously published data regarding nearby genes and the availability of an independent replication cohort add confidence to the observed association.
Conclusion
The genetic architecture of anthracycline cardiotoxicity is complex. Using GWAS we identified a novel susceptibility locus near PRDM2. Pathway analysis suggested that genome repair, metabolism, and pathways relevant for cardiac remodeling influence susceptibility to anthracycline cardiotoxicity. Our findings extend current understanding by identifying a novel risk locus and emphasizing the multifactorial nature of anthracycline cardiotoxicity. This work helps to frame findings from previous candidate studies into a paradigm of genomic injury followed by progressive metabolic and myocardial remodeling. Finally, our findings provide mechanistic insight into anthracycline cardiotoxicity and suggest testable hypotheses for detection and prevention of this adverse effect.
